Literature DB >> 34927008

Metformin for Cardiovascular Protection, Inflammatory Bowel Disease, Osteoporosis, Periodontitis, Polycystic Ovarian Syndrome, Neurodegeneration, Cancer, Inflammation and Senescence: What Is Next?

Moein Ala1, Mahan Ala2.   

Abstract

Diabetes is accompanied by several complications. Higher prevalence of cancers, cardiovascular diseases, chronic kidney disease (CKD), obesity, osteoporosis, and neurodegenerative diseases has been reported among patients with diabetes. Metformin is the oldest oral antidiabetic drug and can improve coexisting complications of diabetes. Clinical trials and observational studies uncovered that metformin can remarkably prevent or alleviate cardiovascular diseases, obesity, polycystic ovarian syndrome (PCOS), osteoporosis, cancer, periodontitis, neuronal damage and neurodegenerative diseases, inflammation, inflammatory bowel disease (IBD), tuberculosis, and COVID-19. In addition, metformin has been proposed as an antiaging agent. Numerous mechanisms were shown to be involved in the protective effects of metformin. Metformin activates the LKB1/AMPK pathway to interact with several intracellular signaling pathways and molecular mechanisms. The drug modifies the biologic function of NF-κB, PI3K/AKT/mTOR, SIRT1/PGC-1α, NLRP3, ERK, P38 MAPK, Wnt/β-catenin, Nrf2, JNK, and other major molecules in the intracellular signaling network. It also regulates the expression of noncoding RNAs. Thereby, metformin can regulate metabolism, growth, proliferation, inflammation, tumorigenesis, and senescence. Additionally, metformin modulates immune response, autophagy, mitophagy, endoplasmic reticulum (ER) stress, and apoptosis and exerts epigenetic effects. Furthermore, metformin protects against oxidative stress and genomic instability, preserves telomere length, and prevents stem cell exhaustion. In this review, the protective effects of metformin on each disease will be discussed using the results of recent meta-analyses, clinical trials, and observational studies. Thereafter, it will be meticulously explained how metformin reprograms intracellular signaling pathways and alters molecular and cellular interactions to modify the clinical presentations of several diseases.
© 2021 American Chemical Society.

Entities:  

Year:  2021        PMID: 34927008      PMCID: PMC8669709          DOI: 10.1021/acsptsci.1c00167

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN: 2575-9108


  376 in total

Review 1.  Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression.

Authors:  Cheng-Ann Winston Ng; Amy Aimei Jiang; Emma Min Shuen Toh; Cheng Han Ng; Zhi Hao Ong; Siyu Peng; Hui Yu Tham; Raghav Sundar; Choon Seng Chong; Chin Meng Khoo
Journal:  Int J Colorectal Dis       Date:  2020-06-26       Impact factor: 2.571

2.  Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC.

Authors:  Giovanni Blandino; Mariacristina Valerio; Mario Cioce; Federica Mori; Luca Casadei; Claudio Pulito; Andrea Sacconi; Francesca Biagioni; Giancarlo Cortese; Sergio Galanti; Cesare Manetti; Gennaro Citro; Paola Muti; Sabrina Strano
Journal:  Nat Commun       Date:  2012-05-29       Impact factor: 14.919

Review 3.  CD4 T-cell differentiation and inflammatory bowel disease.

Authors:  Lauren A Zenewicz; Andrey Antov; Richard A Flavell
Journal:  Trends Mol Med       Date:  2009-04-08       Impact factor: 11.951

4.  Long noncoding RNA H19 participates in metformin-mediated inhibition of gastric cancer cell invasion.

Authors:  Peiwen Li; Linhao Tong; Yongxi Song; Jingxu Sun; Jinxin Shi; Zhonghua Wu; Yao Diao; Yaming Li; Zhenning Wang
Journal:  J Cell Physiol       Date:  2018-09-07       Impact factor: 6.384

Review 5.  The hallmarks of CDKN1C (p57, KIP2) in cancer.

Authors:  Edel Kavanagh; Bertrand Joseph
Journal:  Biochim Biophys Acta       Date:  2011-04-03

6.  Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy.

Authors:  Leigh A Cantrell; Chunxiao Zhou; Alberto Mendivil; Kimberly M Malloy; Paola A Gehrig; Victoria L Bae-Jump
Journal:  Gynecol Oncol       Date:  2009-10-12       Impact factor: 5.482

7.  SIRT6 regulates osteogenic differentiation of rat bone marrow mesenchymal stem cells partially via suppressing the nuclear factor-κB signaling pathway.

Authors:  Hualing Sun; Yanru Wu; Dongjie Fu; Yinchen Liu; Cui Huang
Journal:  Stem Cells       Date:  2014-07       Impact factor: 6.277

Review 8.  Role of the JNK signal transduction pathway in inflammatory bowel disease.

Authors:  Praveen K Roy; Farzana Rashid; Jack Bragg; Jamal A Ibdah
Journal:  World J Gastroenterol       Date:  2008-01-14       Impact factor: 5.742

9.  Metformin inhibits TGF-β1-induced epithelial-to-mesenchymal transition-like process and stem-like properties in GBM via AKT/mTOR/ZEB1 pathway.

Authors:  Yang Song; Yong Chen; Yunqian Li; Xiaoyan Lyu; Jiayue Cui; Ye Cheng; Liyan Zhao; Gang Zhao
Journal:  Oncotarget       Date:  2017-12-15

10.  Association between Growth Differentiation Factor-15 (GDF-15) Serum Levels, Anorexia and Low Muscle Mass among Cancer Patients.

Authors:  Alessio Molfino; Maria Ida Amabile; Giovanni Imbimbo; Veronica Rizzo; Federica Pediconi; Carlo Catalano; Alessandra Emiliani; Roberta Belli; Cesarina Ramaccini; Claudia Parisi; Giuseppe Nigri; Maurizio Muscaritoli
Journal:  Cancers (Basel)       Date:  2020-12-31       Impact factor: 6.639

View more
  7 in total

1.  Diabetes and its Complications.

Authors:  Simon Matoori
Journal:  ACS Pharmacol Transl Sci       Date:  2022-07-12

Review 2.  Protection by metformin against severe Covid-19: An in-depth mechanistic analysis.

Authors:  Nicolas Wiernsperger; Abdallah Al-Salameh; Bertrand Cariou; Jean-Daniel Lalau
Journal:  Diabetes Metab       Date:  2022-05-31       Impact factor: 8.254

Review 3.  A Clinical Perspective of the Multifaceted Mechanism of Metformin in Diabetes, Infections, Cognitive Dysfunction, and Cancer.

Authors:  Elaine Chow; Aimin Yang; Colin H L Chung; Juliana C N Chan
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-02

4.  A Novel Isaindigotone Derivative Displays Better Anti-Proliferation Activities and Induces Apoptosis in Gastric Cancer Cells.

Authors:  Kangjia Du; Chengjie Yang; Zhongkun Zhou; Yunhao Ma; Yanan Tian; Rentao Zhang; Hao Zhang; Xinrong Jiang; Hongmei Zhu; Huanxiang Liu; Peng Chen; Yingqian Liu
Journal:  Int J Mol Sci       Date:  2022-07-21       Impact factor: 6.208

Review 5.  Increased susceptibility to pneumonia due to tumour necrosis factor inhibition and prospective immune system rescue via immunotherapy.

Authors:  Ryan Ha; Yoav Keynan; Zulma Vanessa Rueda
Journal:  Front Cell Infect Microbiol       Date:  2022-09-07       Impact factor: 6.073

Review 6.  Extracellular Vesicles: The Next Generation Theranostic Nanomedicine for Inflammatory Bowel Disease.

Authors:  De-Feng Li; Mei-Feng Yang; Jing Xu; Hao-Ming Xu; Min-Zheng Zhu; Yu-Jie Liang; Yuan Zhang; Cheng-Mei Tian; Yu-Qiang Nie; Rui-Yue Shi; Li-Sheng Wang; Jun Yao
Journal:  Int J Nanomedicine       Date:  2022-09-05

Review 7.  Metformin: A Narrative Review of Its Potential Benefits for Cardiovascular Disease, Cancer and Dementia.

Authors:  Wiebe M C Top; Adriaan Kooy; Coen D A Stehouwer
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.